What is MEI Pharma's market cap?

MEI Pharma (LITS) has a market capitalization of $33.8M and trades on NASDAQ.

Who are MEI Pharma's competitors?

MEI Pharma's key competitors include MicroStrategy Incorporated, AstraZeneca, AbbVie Inc., and others. These companies compete in similar markets and product categories.

Who does MEI Pharma partner with?

MEI Pharma's notable partners include Kyowa Kirin Co., Ltd, Presage Biosciences, Inc., GSR Strategies LLC, and others.

What subsidiaries does MEI Pharma have?

MEI Pharma's subsidiaries include Meadow Merger Sub, Inc..

Where is MEI Pharma headquartered?

MEI Pharma is headquartered in United States of America and employs approximately 28 people. It has been publicly traded since 2003.

MEI Pharma

LITS

Lite Strategy, Inc. is a diversified company that combines biotechnology development with a digital asset treasury strategy.

Market cap

$33.79M+88.5%

Table of contents

Earnings

Q1 2026 report

May 13, 2026

EPS-$0.66Beat by $2.46

Read the full report

Next report

Sep 18, 2026 (in 2 months)

Revenue estimate$5.4M

EPS estimate-$3.12

Competitors

By market cap

AbbVie$441.54B+33.2%

MicroStrategy$33.6B-69.6%

Solana Company $106.8M+1,515%

DeFi Development Corp.$91.0M-73.3%

Upexi$60.0M-51.4%

MEI Pharma$33.8M+93.5%

APU

Apimeds Pharmaceuticals US, Inc$11.1M-46.8%

LM Funding America, Inc.$3.0M-75.3%

By revenue growth

Solana Company +2,109%

DeFi Development Corp.+597%

Upexi+57.8%

AbbVie+9.5%

MicroStrategy+3.0%

By net margin

MicroStrategy1,663.11%-575pp

AbbVie5.79%-1.5pp

Upexi-874.01%-738pp

DeFi Development Corp.-1,136.38%-1,008pp

Solana Company -39,358.87%-2,157pp

Profile

Lite Strategy, Inc. is a diversified company that combines biotechnology development with a digital asset treasury strategy. The company manages a pipeline of novel cancer therapies while utilizing Litecoin as its primary reserve asset to enhance capital efficiency and align with emerging financial technologies. Its core value proposition lies in creating value through clinical development, strategic out-licensing of oncology programs, and long-term innovation in capital structure.

Competitive position

The company is transitioning from a pure-play oncology developer to a hybrid model incorporating a decentralized digital asset treasury strategy. It maintains a competitive position through its specialized CDK9 and PI3Kδ inhibitor assets and its early adoption of Litecoin as a corporate reserve.

GeographiesUnited States, Global

Customer segmentsEnterprise, Healthcare

Business modelIP Licensing, Asset Management, Research and Development

SuppliersContract Manufacturing Organizations (CMOs), Clinical Research Organizations (CROs), Digital asset custodians, Litecoin network miners, Academic research institutions

CustomersGlobal pharmaceutical partners, Oncology patients, Institutional investors, Healthcare systems

CountryUnited States of America

Listed2003

Employees28.0

CEOJustin J. File

SectorHealthcare

IndustryBiotechnology

Websitelitestrategy.com

FilingsSEC EDGAR

Questions, answered.

What is MEI Pharma's market cap?: MEI Pharma (LITS) has a market capitalization of $33.8M and trades on NASDAQ.
Who are MEI Pharma's competitors?: MEI Pharma's key competitors include MicroStrategy Incorporated, AstraZeneca, AbbVie Inc., and others. These companies compete in similar markets and product categories.
Who does MEI Pharma partner with?: MEI Pharma's notable partners include Kyowa Kirin Co., Ltd, Presage Biosciences, Inc., GSR Strategies LLC, and others.
What subsidiaries does MEI Pharma have?: MEI Pharma's subsidiaries include Meadow Merger Sub, Inc..
Where is MEI Pharma headquartered?: MEI Pharma is headquartered in United States of America and employs approximately 28 people. It has been publicly traded since 2003.